最新刊期
      卷 31 ， 期 5 ， 2020
      • DONG Shujie,YANG Li,CHEN Chen,KONG Xianwei,CAI Zheng,DU Yawei,LIU Fang,ZHU Jinping,JIANG Hua,HUANG Jing,ZHANG Xianhua,WEN Jian,LI Xue,HAN Tao,GUO Hongying,CUI Jing,SHUAI Yuan,LI Jing,YAN Yingying,LIU Wei,LI Huibo,YANG Yiheng,LI Zijian,ZHAO Rongsheng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE： To provide reference for improving emergency capacity of the hospital pharmacy department in response to the novel coronavirus pneumonia （COVID-19） epidemic. METHODS ：According to the related regulations and requirements of Law of the People ’s Republic of China on the Prevention and Control of Infectious Diseases ，combined with the situation of COVID- 19 epidemic prevention and control ，and management experience of relevant hospitals ，on the basis of in-depth analysis of drug supply and quality assurance ，drug dispensing management ，provision of clinical pharmaceutical services and other related material support of hospital pharmacy department，integrated emergency management model was constructed for COVID- 19 epidemic prevention and control ，and the precautions and response measures of each link were sorted out. RESULTS ：Integruted emergency management mode for COVID-19 epidemic prevention and control in hospital pharmacy department included but was not limited to human resource management，drug and disinfection products supply management （mainly including key treatment drugs and disinfection product list formulation，control，inventory increase ，etc.）；drug dispensing management （mainly including prescription ，pharmacy window ， planning quantitative reserve ， drug return ， etc.）；clinical pharmaceutical care management （mainly including providing pharmaceutical information support ，online pharmaceutical service ，monitoring drug safety ，etc.）；personnel protection and disinfection （mainly including personnel protection ，environment and window ，equipment and container ，paper prescription disinfection，etc.）；special management of donated drugs ；prevention and control knowledge training ；pharmaceutical education and scientific research management ，etc. CONCLUSIONS ：The integrated emergency management model for epidemic prevention and control is helpful for hospital pharmacy to manage public health emergencies. During the outbreak of COVID- 19，hospital pharmacy department should start integrated emergency management mode for epidemic prevention and control ，strengthen the risk control of each link ，and play a good role in the key functional departments in the special period.  
        关键词：COVID-19;Epidemic prevention and control;Hospital pharmacy department;Integrated emergency management   
        4092
        |
        1
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609489 false
        发布时间：2022-06-21
      • YANG Li,XU Xiaohan,CHEN Chen,YANG Guang,CHEN Lihua,HE Xiaojie,YANG Yiheng,ZHAI Suodi,ZHAO Rongsheng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide drug ，material supp ly and emergency management reference for novel coronavirus （SARS-CoV-2）infection in pharmacy staff in hospital. METHODS ：The method of 5M1E was used to analyze the six main factors，including man ，machine，material，method，environment and measurement of drug ，material supply and emergency management. The relevant prevention and control strategies were put forward. RESULTS & CONCLUSIONS ：In the drug ，material supply and emergency management of epidemic prevention and control ，the man factors were involved ，such as mainly pharmacists from pharmacy departments of medical institutions. At the same time ，the management also involved machine factors such as drug storage，cleaning and disinfection ；material factors such as emergency drugs ，disinfection products ，in vitro diagnostic reagents ， the guarantee of medicine materials for medical team ，investigational products ；methods factors such as relevant management measures；environmental factors such as storage environment and facilities ；measurement factors such as drug use ，drug and substance reserve. In view of the above factors ，it is suggested to strengthen the professional knowledge and communication skills training of pharmacists ，and strengthen humanistic care ，so as to improve their post competency ，communication in emergency response and psychological tolerance. Equipment and materials management shall be strengthened ，and equipment maintenance and disinfection shall be done well to ensure normal use of equipment. According to the evidence-based method ，the emergency drug list should be established. According to the disinfection protection requirements ，the disinfection products should be reasonably selected and their quality and sufficient inventory should be ensured. The qualified in vitro diagnostic reagents should be purchased in time. The investigational products should be managed reasonably according to the relevant requirements of clinical trials ，to ensure the drug and material supply of medical team members. Emergency plans and standard operating procedures shall be formulated，the principle of sympathetic drug use shall be followed ，and the management of off-label drug use and early warning of drug and material shortage shall be done well. Reasonable storage space should be reserved to strengthen environmental monitoring and disinfection. We should strengthen the monitoring and reporting of daily data ，strengthen the quality monitoring ， and accept the independent audit of the third party. Above strategies are helpful to improve the ability of drug supply risk identification and response ability ，and cooperate with the medical team to timely rescue patients.  
        关键词：Novel coronavirus;SARS-CoV-2;Drug supply;5M1E analysis method;Emergency management;Preventive and   
        3342
        |
        2
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609472 false
        发布时间：2022-06-21
      • YAN Yingying,YUAN Xiaoning,YANG Yiheng,YANG Li,LIU Fang,ZHAI Suodi,ZHAO Rongsheng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To pro vide reference for exposure protection countermeasures for Novel coronavirus （SARS-CoV-2） infection in hospital pharmaceutical staff. METHODS ：According to the recommendations of related medical staff protection guideline，combined with the characteristics and prevention and control requirements of novel coronavirus pneumonia （COVID- 19），based on the basic principle of exposure protection ，actual exposure risk of infections for hospital pharmaceutical staff were evaluated，and the countermeasures for exposure protection were constructed under the epidemic condition of COVID- 19. RESULTS：According to the standard prevention principle and the risk evaluation of infection exposure ，most of the pharmaceutical posts in the hospital belonged to low-risk exposure posts ，and only a few posts belonged to medium-and high-risk exposure posts. Personal protective equipment should be provided according to the exposure risk level of different pharmaceutical posts and work demand. At the same time ，infection protection training should be strengthened ；environment and facilities in pharmacy should be cleaned and disinfected. CONCLUSIONS ：Standard prevention principle should be followed by hospital pharmaceutical staff during epidemic period. Based on the characteristics and exposure risks of pharmacy posts ，and according to the regulations of the hospital，personal protection for hospital pharmaceutical staff should be conducted according to the exposure risk level determined by the pharmaceutical department and relevant management regulations to avoid over-protection or inadequate protection ，so as to ensure the smooth and safe development of pharmaceutical care.  
        关键词：Novel coronavirus;COVID-19;Hospital pharmaceutical staff;Exposure protection   
        3069
        |
        2
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609459 false
        发布时间：2022-06-21
      • YI Zhanmiao,GUO Hao,QI Shibo,ZHOU Tiantian,ZHAO Rongsheng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To p rovide reference for related pharmacy work for developing evidence-based pharmacy information support to respond for novel coronavirus pneumonia （COVID-19） epidemic. METHODS ：The PubMed，CNKI and Wanfang database were consulted to obtain treatment progress of COVID-19，prohibited for use with lopinavir/ritonavir and adverse drug reactionas until February 12，2020；so were package insert and UpToDate at the same time. Those information were summarized and evaluated. RESULTS & CONCLUSIONS ：Totally 14 literatures introduced chemical drugs for COVID- 19，involving 7 categories， 20 kinds of chemical drugs as antiviral drugs （interferon α/interferon α-2 β ， lopinavir/litonavir， etc.）， immunomodulatory agents （such as glucocorticoid ，gamma globulin ），antimalarial drugs （such as chloroquine phosphate ）. The existing evidence of drug treatment mainly comes from in vitro cell test or currently progressing RCT ，with low-level evidence and recommendation intensity （Oxford evidence level is level 5，recommendation intensity is level D ）. For lopinavir/ritonavir that recommended in the diagnosis and treatment recommendations for COVID- 19 published by the National Health Commission ，it is a CYP3A inhibitor ，which resulted in increased plasma concentrations of some medications such as antiarrhythmic drugs ，antitumor targeted drugs and antibacterial drugs ，and should not be used in combination with drugs such as afzosin ，ivabradine，amiodarone， etc. Its common adverse reactions mainly involved igestive system （diarrhea，taste disorders ，vomiting，etc.），respiratory system （upper respiratory tract infection ），endocrine and metabolic system （hypercholesterolemia，etc.），skin and its appendents （skin rash），which should be monitored clinically.  
          
        3665
        |
        322
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609446 false
        发布时间：2022-06-21
      • YING Yingqiu,REN Zhenyu,SHI Weilong,ZHAO Yue,YANG Li,ZHAO Rongsheng,ZHAI Suodi
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide re ference f or hospital pharmacy prevention and control management during novel coronavirus（SARS-CoV-2）infection epidemic period. METHODS ：Based on 5M1E analysis method ，according to the needs of epidemic prevention and control ，it is necessary to analyze the risks of 5 aspects as personnel ，equipment and materials ，methods， environment，monitoring of the pharmacy work in hospital ，and establish the prevention and control strategy of hospital pharmacy infection in response to the epidemic situation of novel coronavirus pneumonia （COVID-19）according to the corresponding risks. RESULTS & CONCLUSIONS ：Personnel management strategies include carrying out pharmacist prevention and control training ， focusing on physical and mental health of pharmacists during infection prevention and control ；equipment and materials management strategies include strengthening equipment disinfection management and strengthening the management of materials for infection prevention and control ；method management strategies include developing emergency plans for infection prevention and control，standardizing individual infection prevention and control method ；environment management strategies include environment cleaning and disinfection management ，infection exposure management of related medical material ，medical waste management ； monitoring management strategies include strengthening pharmacists infection monitoring and evaluating pharmacists ’prevention and control effect. By establishing the strategy for COVID- 19 epidemic prevention and control ，it can effectively guiding pharmacists to carry out epidemic prevention and control.  
        关键词：5M1E analysis method;COVID-19;Hospital pharmacy;Infection prevention and control strategies   
        2440
        |
        193
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609433 false
        发布时间：2022-06-21
      • CHEN Jingze,HU Mingle,LUO Jiawei,ZHANG Wei,ZHANG Dingyu
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To shar e the experienc e of pharmaceutical care in Wuhan Jinyintan Hospital （herein after refers to “our hospital ”）under the condition of novel coronavirus pneumonia （COVID-19）epidemic，and to provide reference for other hospitals to deal with public health emergencies. METHODS ：The situation of pharmaceutical care in our hospital under the condition of COVID- 19 epidemic was summarized and shared ，including the epidemic prevention and control management （regional division ，disinfection management ，pharmacy personnel training ），supply of drugs and disinfection products ，the monitoring and education of rational drug use by information technology. RESULTS ：The pharmacy department of our hospital divided the activity scope into clean area ，potential pollution risk area ，semi pollution area ，and implement different disinfection management. All pharmacists received training ，involving personal health protection ，prevention and control knowledge of COVID-19，health status monitoring ，etc. For supply and guarantee of drugs and disinfectants ，the epidemic drug list of our hospital was formulated ，drugs and disinfectants were purchased accurately and stored in a standardized way. 24 h response telephone was set up in the clinical pharmacy room to receive consultation from clinicians on drug use at any time. The drugs mentioned in the COVID- 19 diagnosis scheme were compared in terms of the mechanism of action and the medication of special populations to form a tablet ，so as to help clinical rational choice treatment drug. CONCLUSIONS ：The pharmaceutical care in the designated hospital of COVID- 19 is a professional and complicated work ，involving a wide range of aspects. Pharmacy department must respond actively and adjust the strategy in time so as to play an important role in improving the ability of medical treatment.  
        关键词：COVID-19;Designated hospital;Pharmaceutical care   
        2348
        |
        195
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609423 false
        发布时间：2022-06-21
      • KONG Fanxin,MA Aixia,LI Hongchao,TANG Wenxi
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide reference for scientific decision-making of evaluation and application of clinical comprehensive value of drugs from the perspective of the public decision-making in China. METHODS ：Based on relevant documents and literatures ，drug clinical comprehensive value in other countries and areas ，the core indicators of drug clinical comprehensive value evaluation in China were confirmed. The concept and evaluation methods of each indicator were evaluated ， and relevant suggestions were put forward. RESULTS & CONCLUSIONS ：It’s suggested that the core indicators of China ’s drug clinical comprehensive value evaluation are safety and efficacy ，economy and affordability ，accessibility and fairness adherence ， suitability. The concepts of safety ，efficacy，economy，affordability and adherence indexes are clearly defined ，evaluation methods are systematic ，data sources are sufficient ，and international consensus exists in research design. There is no uniform definition of accessibility which composed of availability ，deliverability，availability，affordability and timeliness. The concept of equity is clearly defined and the evaluation method is systematic ，but the data source is insufficient. Appropriateness is evaluated by drug suitability index but there is no clear definition. Taking efficacy as an example ，efficacy includes intermediate indicators ，outcome indicators and quality of life indicators ，which are often confirmed by epidemiological research ，systematic evaluation and expert consensus. It ’s suggested that the Real World Study data should be used as much as possible when selecting or formulating the clinical comprehensive value indicators of drugs. With the help of multi-criteria decision-making analysis ，technical support should be provided by professional evaluation institutions ，and with the support of experts and researchers ，the above indicators should be empowered to form the clinical comprehensive value judgment of a drug by different public decision-making departments ，so as to decide whether to purchase ，use clinically ，or incorporate medical insurance reimbursement.  
          
        228
        |
        12
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609412 false
        发布时间：2022-06-21
      • ZHU Zirong,ZHANG Lingli,YAN Jianzhou,SHAO Rong
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide reference for deepening the reform of medical insurance payment mode in China. METHODS：By analyzing the specific reform process and driving factors of American Medicare ，and considering the background of current payment reform in China ，then some suggestions were put forward to promote the reform of medical insurance payment mode in China. RESULTS & CONCLUSIONS ：The payment mode of Medicare in the United States had undergone three stages ， which were post-payment system ，pre-payment system and value-based payment system. The payment modes included payment by service items ，payment by disease diagnosis related groups （DRGs）and payment by service value. The change was the result of the comprehensive effect of the three systems of technology ，politics and social culture in the United States. The demand for reasonable treatment and control fees drove the change from post-payment system to pre-payment system ，while the crisis of service quality ， the rise of service cost and the contradiction between doctors and patients drove the change to value-based payment. Payment mode reform had a positive impact on Medicare in the United States ，reducing medical expenditure and improving the quality of service. It is suggested that China should draw lessons from the experience of the United States in reforming the prepayment system nationwide on the basis of the current DRGs pilot projects. Meanwhile ，in order to avoid the medical quality crisis in the later period of the United States ，it is necessary to introduce the concept of value-based payment ，establish incentive and restraint mechanisms and strengthen the construction of the regulatory supporting system for the whole process.  
        关键词：American Medicare;Medicare payment mode reform;Payment by disease diagnosis related groups;Driving factors   
        322
        |
        4
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609402 false
        发布时间：2022-06-21
      • CHEN Jiani,CHEN Yongfa
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide reference for improving the supporting system of drug safety governance in China. METHODS：Through analyzing the main ways ，characteristics and effectiveness of drug safety governance in Australia ，the suggestions for building drug safety governance system in China were put forward initially. RESULTS & CONCLUSIONS ：The methods of Australia ’s drug safety governance are to conduct division of labor between the federal and state/territory governments ， advanced-voluntary-bundled-payment-model. conduct policy consultations with different related entities separately ，guide industry self-discipline based on industrial development level，and support industry to participate in drug advertising supervision. Australia ’s drug safety governance has the characteristics of large information sharing channels ，increasing the transparency of government work ，carrying out targeted education and enhancing the governance capacity of participants etc. It has achieved significant improvement in the occurrence of drug recall events，and significant increase in the satisfaction of stakeholders in the communication activities of drug regulatory authorities. In contrast，the participation consciousness and ability of relevant entities in China are still not strong ，and the system to ensure the participation of these entities is not yet sound. It is recommended that China should pay more attention to the communication between the upper and lower levels of governments ，conduct targeted education or training for principals of non-government entities， implement the policy consultation rights of non-government entities ， as well as guide self-discipline based on self-management ability of industry entities so as to initially establish drug safety governance system in China ，and enhance the governance efficiency.  
        关键词：Australia;Drug safety;Governance system;Enlightenment   
        149
        |
        6
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609394 false
        发布时间：2022-06-21
      • WANG Jie,SU Shaofeng,YAO Renchuan,REN Chaoxiang,PEI Jin,CHEN Jiang
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To investigate the correlation of storage life and effective composition content with color value of Carthamus tinctorius ，and to provide reference for the quality evaluation of C. tinctorius with different years of storage. METHODS：Using 24 batches of C. tinctorius from same place of production with different years of storage （0，1，2 years，8 batches each type ）as samples ，the contents of hydroxysafflor yellow A （HSYA）and kaempferol were determined by HPLC. Color value [lightness value （L*），red-green value （a*），yellow-blue value （b*）] were determined by spectrophotometer. SPSS 19.0 statistical software was used to analyze the correlation of storage life and effective composition content with color value. RESULTS：Kaempferol content was still high after 1 year or 2 years of storage （0.161％，0.061％，respectively）. However ，the content of HSYA decreased with the prolongation of the storage life （the average content of HSYA were 2.46％，1.58％，and 1.51％ after storage 0，1 and 2 years，respectively），and the color of the drug became darker （a* value decreased ）. Results of correlation analysis showed that the content of HSYA was positively associated with color value L*，a*（r＝0.430，0.781，P＜0.05 or P＜0.01）；the content of HSAY was negatively associated with storage life （r＝－0.777，P＜0.01）. There was no correlation between the remaining variables （P＞0.05）. CONCLUSIONS ：The longer the storage life ，the darker the color and the lower the content of HSYA ，so it is not suitable for over year and multiyear preservation.  
        关键词：Carthamus tinctorius;Storage life;Hydroxysafflor yellow A;Kaempferol;Color;Quality;Correlation analysis   
        230
        |
        11
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609379 false
        发布时间：2022-06-21
      • YAN Xueling,SHI Zheng,ZHANG Yun
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To study the pharmacological effects and possible molecular mechanism of the superior components in Fagopyrum dibotrys . METHODS ：Based on network pharmacology ，by selecting DL ＞0.18 and OB ＞30％ as criteria ，superior components of F. dibotrys were screened out ，using the traditional Chinese medicine integrated pharmacology （TCMIP）platform. Pharm Mapper database was utilized to obtain the potential targets of each components ；Kyoto gene and genome database （KEGG） signal pathway analysis and gene ontology （GO）bioprocess enrichment analysis were performed for target protein with DAVID database（all using P＜0.05 as criteria ）. RESULTS ：15 kinds of superior components [such as quercetin ，luteolin，procyanidin B 1， （+）catechin and β-sitosterol，etc.] and 114 target proteins （such as estradiol 17-β-dehydrogenase 1，cAMP specific 3，5-cyclic phosphodiesterase 4D，vitamin D 3 receptor，uridine cytidine kinase 2，urokinase triphosphate encoded by HRAS gene ，etc.）were screened out ，involving 34 important pathways ，like MAPK signaling pathway ，VEGF signaling pathway ，chemokine signaling pathway and insulin signaling pathway ；among them ，11 were cancer-related pathways ，7 were metabolic-related pathways ，4 were endocrine-related pathways. The involved molecular functions included steroid receptor activity ，ligand dependent nuclear receptor activity，protein kinase activity ，etc.；cell components included cell fluid ，cell fragment ，soluble part ，etc.；biological processes included the regulation of apoptosis ，the process of organic response ，the process of endogenous stimulation response ，etc. CONCLUSIONS：F. dibotrys may play anti-tumor effects ，anti-inflammatory effects ，regulation of glycolipid metabolism by acting on MAPK signaling pathway ，VEGF signaling pathway ，chemokine signaling pathway and insulin signaling pathway.  
          
        173
        |
        9
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609368 false
        发布时间：2022-06-21
      • DU Mengjiao,ZHONG Yanmei,DENG Shanbin,YU Chuqin,CHEN Lishi,CAI Yanqu
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To study the mecha nism of Bambuterol hydrochloride in the improvement of chronic obstructive pulmonary disease （COPD）model rats ，and to find the potential biomarker. METHODS ：Totally 30 rats were randomly divided into normal group ，model group and bambuterol hydrochloride group （3.3 mg/kg），with 10 rats in each group ；COPD model was established by lipopolysaccharide （LPS）infusion combined with smoking in model group and bambuterol hydrochloride group. After modeling ，bambuterol hydrochloride group was given relevant medicine intragastrically ，normal group and model group were given constant volume of normal saline intragastrically ，once a day ，for consecutive 45 d. After last medication ，the serum sample and alveolar lavage fluid of rats were collected. The levels of interleukin- 6（IL-6）and tumor necrosis factor-α（TNF-α）in alveolar lavage fluid were detected by ELISA. The serum metabolites were detected by LC-MS and analyzed by metabolomics. Orthogonal partial least squares discriminant analysis （OPLS-DA）was used to screen out the differential metabolites. The potential biomarkers were identified based on the related literature ，and the metabolic pathway enrichment analysis was carried out by MetPA analysis platform. RESULTS ：Compared with normal group ，the levels of IL- 6 and TNF-α in alveolar lavage fluid of rats were increased significantly in model group （P＜0.05）. Compared with model group ，the levels of IL- 6 and TNF-α in alveolar lavage fluid of rats were decreased significantly in bambuterol hydrochloride group （P＜0.05）. Results of metabolomics and OPLS-DA showed that 21 differential metabolites and 12 potential biomarkers were found （including maleylpyruvate ， hydroxypyruvate， tartronate semialdehyde，etc.）. Bambuterol hydrochloride can significantly reduce the levels of maleylpyruvate ，methylselenocysteine and 5-deoxy-D-glucuronic acid （P＜0.05）， while increase the levels of hydroxypyruvate ， tartronate semialdehyde and. These biomarkers were mainly @163.com concentrated in pentose phosphoric acid pathway ，glyoxyli acid and tricarboxylic acid metabolism pathway ，followed by 开发。E-mail：pn333@163.com inositol phosphoric acid metabolism pathway ，arginine and tyrosine metabolism pathway ，glycine，serine and threonine metabolism pathway. CONCLUSIONS ：The mechanism of bambuterol hydrochloride improving COPD may be associated with the decrease of the levels of TNF-α and IL-6，as well as the pathway of amino acid metabolism ，energy metabolism and lipid metabolism.  
          
        135
        |
        6
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609353 false
        发布时间：2022-06-21
      • FENG Jingqian,HU Weinan,XU Liping,LI Jiangyan,WANG Siwei,SONG Jianfeng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To establish a method for the simultan eous determination of the contents of 12 flavonoids in Quzhiqiao. METHODS ：HPLC method was adopted. The determination was performed on Agilent Extend C 18 column with mobile phase consisted of 0.1％ formic acid-acetonitrile （gradient elution ）at the flow rate of 1.0 mL/min. The column temperature was set at 35 ℃. The detection wavelength was set at 330 nm，and sample size was 10 μL. The contents of 12 components（such as eriocitrin，narirutin，naringin，naringenin，hesperidin，neohesperidin，hesperide hydrate ，luteolin，hesperide，nobiletin，hesperetin and hesperidolactone ）in 10 batches of Quzhiqiao from different collection places were determined. RESULTS ：The linear range of eriocitrin，narirutin，naringin，naringenin，hesperidin，neohesperidin，hesperide hydrate ，luteolin，hesperide，nobiletin，hesperetin and hesperidolactone were 1.65-16.51，4.50-45.02，35.41-354.12，4.11-41.12，2.29-22.86，34.96-349.56，1.42-14.15，1.50-15.04， 1.83-18.28，1.51-15.08，1.61-16.12，1.28-12.84 μg/mL，respectively（all r＞0.999 7）. The detection limits were 0.165 1，0.450 2， 3.541 2，0.411 2，0.228 6，3.495 6，0.141 5，0.150 4，0.182 8，0.150 8，0.161 2，0.128 4 μg/mL，respectively. The limits of quantitation were 0.547 8，1.487 4，11.663 3，1.360 3，0.758 3，11.594 9，0.466 3，0.497 1，0.601 2，0.499 9，0.532 3，0.424 6 μg/mL，respectively. RSDs of precision （n＝6），reproducibility（n＝6）and stability （24 h，n＝7）tests were all lower than 3％. The average recoveries were 99.50％，99.61％，98.18％，98.85％，98.48％，98.50％，98.25％，99.91％，103.13％，98.82％， 98.44％ ， 100.29％ （RSD＝1.49％ -2.38％ ， n＝6）. The contents of the above 12 components in 10 batches of samples from different collection places were 1.995 5-2.648 8，4.317 7- 5.005 1，33.215 5-34.054 6，3.140 4-3.471 5，3.221 2-3.748 8， 42.746 6-44.026 6，0.202 7-0.239 4，0.191 2-0.208 8，0.080 3- 0.097 9，0.291 9-0.307 1，0.119 9-0.149 1，0.082 7-0.089 8 mg/g. CONC LUSIONS：The method is accurate ，reliable，simple and efficient，which can be used to simultaneous determination of the contents of 12 flavonoids in Quzhiqiao ，and to provide reference for the establishment of quality control standards of Quzhiqiao.  
        关键词：Quzhiqiao;Flavonoids;Naringin;Neohesperidin;Content determination;HPLC   
        215
        |
        7
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609339 false
        发布时间：2022-06-21
      • DONG Danhua,LIU Yujun,LI Yanan,HU Xianghao,SUN Ping,LI Ting,LIU Juyan,GAO Peng
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To establish the content determin ation method of ferulic acid ，verbascoside，ligustilide and astragaloside in Shengyu decoction lyophilized powder. METHODS ：HPLC method was adopted to determine 4 components in 3 batches of lyophilized powder. The determination of ferulic acid ，verbascoside and ligustilide was performed on Inertsil ODS-SP C 18 column with mobile phase consisted of methanol- 0.1％ phosphoric acid （gradient elution ）at the flow rate of 1.0 mL/min；detector was diode array detector ；detection wavelength was set at 330 nm；column temperature was 30 ℃，the sample size was 10 μL. The determination of astragaloside was performed on Kromasil C 18 column with mobile phase consisted of acetonitrile-water （32∶68，V/ V）；detector was evaporative light scattering detector ；the drift tube temperature wa s 100 ℃，the carrier gas （air）flow rate was 2.5 L/min at the flow rate of 1.0 mL/min；column temperature was 30 ℃，the sample size was 10 μL. RESULTS：The linear ranges of ferulic acid ，verbascoside，ligustilide and astragaloside were 0.050 15-10.03 μg（r＝0.999 8），0.067 80-13.56 μg（r＝ 0.999 9），0.057 30-11.46 μg（r＝0.999 5），1.128-11.28 μg（r＝0.999 3），respectively. The detection limits were 2.12×10－4，1.30× 10－3，8.02×10－4，1.09×10－3 μg，respectively. The limit of quantification were 7.43×10－4，3.87×10－3，2.34×10－3，3.36×10－3 μg， respectively. RSDs of precision ，stability（12 h）and reproducibility tests were all lower than 2％（n＝6）. Average recovery rates were 99.6％（RSD＝0.83％，n＝6），100.9％（RSD＝1.07％，n＝6），98.8％（RSD＝0.84％，n＝6）and 101.3％（RSD＝0.99％， n＝6），respectively. The contents of ferulic acid ，verbascoside，ligustilide and astragaloside in 3 batches of samples were 1.225-1.248， 0.413-0.424， 0.325-0.332， 0.394-0.404 mg/g， respectively （RSDs among batches were lower than 1.5％ ）. CONCLUSIONS：Established method is stable ，reproducible，rapid and accurate for the content determination of ferulic acid ， verbascoside， ligustilide and astragaloside in Shengyu  
          
        147
        |
        9
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609321 false
        发布时间：2022-06-21
      • WANG Yali,LIU Yue,BAN Lu,LI Xiaolu,CHENG Xiaokun,REN Fengzhi,ZHANG Xuexia
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To establish th e method for the determination of related substances in fidaxomicin raw material. METHODS：The detection ability of NP-HPLC-UV ，RP-HPLC-ELSD and RP-HPLC-UV systems for the related substances in fidamycin raw material was investigated and the best chromatographic system was selected . The HPLC detection method for the related substances was established. The detection was performed on Agilent Eclipse XDB C 18 column with mobile phase A consisted of 0.2％ triethylamine buffer solution （pH 3.8）-acetonitrile（55∶45，V/V），mobile phase B consisted of 0.2％ triethylamine buffer solution（pH 3.8）-acetonitrile（20∶80，V/V）at the flow rate of 1.0 mL/min（gradient elution ）；the detection wavelength was set at 230 nm，and column temperature was 35 ℃；the sample size was 10 µL. Calculation of the content of related substances was principal component self-control method without correction factor. RESULTS ：The impurities C and F could not be separated effectively in NP-HPLC-UV system. In RP-HPLC-ELSD system ，only impurities C ，D，E and F could be detected. In RP-HPLC-UV system ，11 impurities could be detected. In the study of methodology ，the linear ranges were 0.5-20.0 μg/mL for fidaxomicin（R2＝0.999 9）；the LOD was 0.05 ng，LOQ was 0.15 ng；RSDs of reproducibility and intermediate precision tests were less than 2.0％（n＝6）；average recovery was 98.4％（RSD＝3.6％，n＝9）. The sum of impurities in 3 batches of raw materials were 0.53％，0.51％，0.51％，respectively. CONCLUSIONS ：The effect of detecting impurities by RP-HPLC-UV are the best. Established method is specific and sensitive ，and can be used for the determination of related substance in fidaxomicin raw material.  
          
        126
        |
        6
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609304 false
        发布时间：2022-06-21
      • SUN Ting,JIANG Jianguo,ZHANG Jing,ZHANG Xiru,XU Yanmei,WANG Liu,JIANG Ning
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To investigate the in vitro quality consistency of domestic Nitroglycerin table t imitative preparation and reference preparation （original drug ）. METHODS ：The contents of nitroglycerin and related substances in 1 batch of Nitroglycerin tablet reference preparation （manufacturer A ）and 4 batches of imitative preparation （manufacturer B ，C，D，E） were determined according to Nitroglycerin Tablet Import Drugs Registration Standard JX 20010267. The paddle method of dissolution determination method was adopted ，with the rotating speed of 50 r/min. HPLC method was adopted to determine the dissolution amount of 5 batches of above preparations in 4 kinds of dissolution mediums （pH 1.2 hydrochloric acid solution ，pH 4.0 acetate buffer solution ，pH 6.8 phosphate buffer solution ，water） within 10 min.The accumulative dissolution rate was calculated，and dissolution curves of samples were drawn.The similarity of the dissolution curves was evaluated by calculating similarity factor （f2）of 2，5，8 min accumulative dissolution rate. RESULTS ：The contents of nitroglycerin in the preparations from manufacturer A ，B，C，D，E were 99.8％，98.3％，94.0％，93.3％，96.7％，respectively（n＝2）；the contents of related substance were 0.46％，0.55％，0.63％，0.72％，0.49％，respectively（n＝2）. Using reference preparation of manufacturer A as control，f2 of imitative preparation from manufacturer B ，C，D，E were 74，28，25，67 in pH 1.2 hydrochloric acid solution ；76， 26，28，84 in pH 4.0 acetate buffer solution ；79，39，35，71 in pH 6.8 phosphate buffer solution ；69，32，37，62 in water ， respectively. CONCLUSIONS ：The method is suitable for in vitro quality consistency evaluation of Nitroglycerin table timitative preparation. Compared with reference preparation ，the contents of main components in the imitative preparations from manufacturer C，D are lower ；in vitro dissolution curves of those imitative preparation are not similar to reference preparation .  
          
        312
        |
        21
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609287 false
        发布时间：2022-06-21
      • LIANG Yuting,LIU Xiaoyun,PAN Jingling,WU Xiaoshi,HUANG Xiaotong,TANG Chunping,SHEN Zhibin
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To study the effects of different penetration enhancers on in vitro transdermal permeation of Flavaspidic acid BB cream. METHODS ：Flavaspidic acid BB cream was prepared ，containing 11 kinds of different penetration enhancers as 1％ azone，2％ azone，3％ azone，4％ azone，1％ menthol，1％ propylene glycol ，1％ oleic acid ，1％ azone+1％ menthol，1％ azone+1％ propanediol，1％ azone+1％ oleic acid or 1％ menthol+1％ propanediol. Modified Franz diffusion cell was adopted using abdominal skin of isolated male rat as transdermal barrier. The content of flavaspidic acid BB was determined by UPLC. The accumulative transdermal amount （Q24 h）and percutaneous permeability （Jss）within 24 h were calculated ；and compared with Flavaspidic acid BB cream without transdermal enhancer ，the enhancement ratio （ER）was calculated. RESULTS ： Q24 h of Flavaspidic acid BB cream with above 11 kinds of transdermal enhancers were （82.96±7.15），（80.17±0.66），（78.22± 1.87），（73.53±1.24），（35.65±2.23），（34.02±1.73），（42.68±2.66），（33.94±1.37），（34.16±1.54），（46.78±1.21），（43.66±1.69） μg/cm2，respectively. Jss value were （5.26±0.10），（4.69±0.12），（4.45±0.45），（4.00±0.06），（3.74±0.33），（3.23±0.18）， （3.73±0.53），（3.14±0.47），（3.54±0.11），（3.98±0.34），（4.34±0.14）μg（/ cm2·h），respectively. ER were 2.055，1.831，1.738， 1.564，1.462，1.263，1.456，1.227，1.385，1.557，1.698，respectively. CONCLUSIONS ：All of the above transdermal absorption enhancers can enhance the percutaneous absorption of Flavaspidic acid BB cream ，among which ，1％ azone is the best.  
        关键词：Flavaspidic acid BB cream;Transdermal absorption enhancer;Transdermal permeability;in vitro   
        156
        |
        8
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609274 false
        发布时间：2022-06-21
      • LIU Xue,QIU Hongyan,PENG Jing,LIU Chunyan,QU Shuyue,MA Ying,XU Qianli,SHEN Xiangchun,TAO Ling,MAO Xiangjun
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To optimi ze and improve the quality standard for Keqing capsules. METHODS ：According to general rule 0502 method stated in 2015 edition of Chinese Pharmacopeia （part Ⅳ），TLC method was used to identify Reineckia carnea and Morus alba in Keqing capsules [the developing solvents were dichloromethane-ethyl acetate-formic acid （10 ∶ 4 ∶ 0.2，V/V/V） and ethyl acetate-carbinol-ammonia （12 ∶ 2 ∶ 1，V/V/V），respectively]. The contents of morphine and codeine phosphate in Keqing capsules were determined by HPLC. The determination was performed on XBridge C 18 column with mobile phase consisted of acetonitrile-0.01 mol/L potassium dihydrogen phosphate aqueous solution （pH value adjusted to 2.7 with 5％ phosphoric acid solution）（5 ∶ 95，V/V）at the flow rate of 1.0 mL/min. The detection wavelength was set at 210 nm，and the column temperature was 35 ℃. The sample size was 10 µL. RESULTS ：In TLC of R. carnea and M. alba in samples ，same color spots were shown in the correspon ding positions of reference substance chromatogram without interference from negative control. The linear range of morphine and codeine phosphate were batches of Keqing capsules were 0.97-1.37，0.16-0.37 mg/g，respectively. CONCLUSIONS ：TLC identification method for R. carnea and M. alba ，as well as HPLC content determination method for morphine and codeine phosphate in Keqing capsules are established；the method is simple ，accurate and reliable with strong specificity ，which improves the quality standard of Keqing capsules.  
        关键词：Keqing capsules;Quality standard;Morphine;Codeine phosphate;TLC;HPLC   
        167
        |
        6
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609256 false
        发布时间：2022-06-21
      • WU Dan,LIU Bin,ZOU Yu
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To develo p a method for simultaneous determination of chlorogenic acid ，paeoniflorin，hesperidin， ammonium glycyrrhizate ，limonin，nobiletin，tangeretin and lobetyolin in Shenqi jianwei granules. METHODS ：UPLC-Q-Exactive quadrupole electrostatic field orbital hydrazine high resolution mass spectrometry method was adopted. The determination was performed on Hypersil Gold C 18 column with a mobile phase consisted of acetonile- 0.1％ formic acid （gradient elution ）at the flow rate of 0.4 mL/min. The column temperature was set at 35 ℃，the sample size was 1 μL. High resolution full scan experiments was performed over the range of m/z 100-1 000 in heating electro-spray lonization and positive mode to extract the accurate mass of analytes. The contents of 8 components were determined in 3 batches of samples from 2 manufacturers. RESULTS ：The linear range of chlorogenic acid ，paeoniflorin，hesperidin，ammonium glycyrrhizate ，limonin，nobiletin，tangeretin and lobetyolin were 0.12-1.46，3.51-42.15，2.71-32.55，1.76-21.10，0.04-0.46，0.04-0.24，0.02-0.21 and 0.01-0.25 μg/mL，respectively（all r≥0.999 0）. The limits of quantitation were 6.06，0.04，0.03，0.02，7.60，0.05，0.02，6.25 ng/mL，respectively. The limits of detection were 3.03，0.01，0.01，0.01，3.80，0.01，0.01，2.50 ng/mL，respectively. RSDs of precision ，reproducibility and stability （24 h）tests were all lower than 5％（n＝6）. Average recoveries were 93.16％-97.78％（RSD≤5％，n＝6）. The contents of 8 components in 3 batches of samples were 12.62-13.20，265.01-472.26，234.20-278.90，173.10-255.74，2.32-2.83，2.37-3.58，0.79-1.22，0.91-1.78 μg/g，respectively. CONCLUSIONS ：The established method is simple ，convenient，rapid，accurate，highly reproducible and sensitive，which can be used for quality control of Shenqi jianwei granules.  
          
        213
        |
        11
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609248 false
        发布时间：2022-06-21
      • YAN Li,ZHOU Xiaoying
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To study the in vitro anti-bacterial activity and potential mechanism of ellagic acid on Streptococcus mutans，and to provide evidence for its prevention and treatment of dental caries. METHODS ：Using Compound chlorhexidine gargle as positive control ，5％DMSO as negative control ，bacteriostasis experiment was conducted by the method of drilling hole ， and bacteriostatic effects of 50，25，12.5，6.25，3.125，1.562 5 mg/mL ellagic acid on S. mutans was preliminarily determined by measuring the diameter of bacteriostatic ring. The minimal inhibitory concentration （MIC）and minimal bactericidal concentration （MBC）of ellagic acid on S. mutans were determined by microdilution method. Using 5％ DMSO as negative control ，the effects of 1/8 MIC，1/4 MIC，1/2 MIC and MIC ellagic acid on the formation of S. mutans biomembrane was determined by crystal violet staining. The changes of the biomembrane structure under the action of 1/2 MIC ellagic acid were observed by microscopy after fluorescence staining. Phenol sulfuric acid method and reducing coenzyme Ⅰoxidation method were used to determine inhibitory effects of 1/8MIC，1/4MIC，1/2MIC，MIC ellagic acid on S. mutans on extracellular polysaccharide （EPS）as well as effect on the activity of lactate dehydrogenase （LDH）in extracellular matrix. RESULTS ：Ellagic acid with concentration of 12.5～50 mg/mL produced an inhibitory ring on S. mutans with diameter greater than 15 mm. Under the action of 50 mg/mL ellagic acid ，the diameter of bacteriostatic ring was the same as that of Compound chlorhexidine gargle . MIC and MBC of ellagic acid to S. mutans were 12.5 mg/mL and 25 mg/mL. The survival rate of bacterial biomembrane after 1/8MIC-MIC ellagic acid treatment was significantly lower than that of the negative control （P＜0.01），and had a certain dose-response trend. After MIC ellagic acid treatment，the survival rate of bacterial biomembrane was （16.41±1.346）％. After fluorescence staining ，the structure of bacterial biomembrane was destroyed by 1/2 MIC ellagic acid. After treated with 1/8MIC-MIC ellagic acid ，its inhibitory rates on water-soluble EPS and water-insoluble EPS were increased significantly ，compared with negative control （P＜0.01）. After treated with 1/4MIC-MIC ellagic acid ，the activity of LDH in the extracellular matrix of bacteria increased significantly ，compared with negative control （P＜0.01），in dose-effect dependent trend. CONCLUSIONS ：Ellagic acid can inhibit the growth of S. mutans ，the mechanism of which may be associated with inhibiting EPS production ，reducing bacterial adhesion ，destroying bacterial cell membrane.  
          
        282
        |
        10
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609238 false
        发布时间：2022-06-21
      • LIU Haijiao,WU Yuxia,XU Wei
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To evaluate the economics of first-line therapy drug for metastatic renal cell carcinoma （mRCC）as sunitinib，sorafenib and pazopanib ，and to provide reference for the adjustment of medical insurance list and clinical medication decision. METHODS ：Using“metastatic renal cell carcinoma ”“mRCC”“sunitinib”“sorafenib”“pazopanib”“cost-effectiveness” “cost-utility”“cost-benefit”“economic analysis ”as the Chinese and English retrieval words ，relevant literatures published during Jan. 1st，2006 to Jul. 15th，2019 were retrieved from PubMed ，Web of Science ，the Cochrane Library ，CNKI，Wanfang database ， VIP. The literatures were screened according to inclusion and exclusion criteria . The quality of the included literatures was evaluated with CHEERS scale. The effectiveness and economy of sunitinib ，sorafenib and pezoparib in the treatment of mRCC were compared qualitatively after the relevant data were extracted. RESULTS ：A total of 10 literatures were included ，and the total coincidence rates of 7 literatures over 75.00％. Among the 4 literature studies of sulatinib vs. sorafenib ，3 literature studies pointed out that sulatinib was the absolute advantage scheme ，and 1 literature study pointed out that sorafenib was more economical ； among the 6 literature studies of sunitinib vs. pezoparib ，4 literature studies indicated that pezoparib was the absolute advantage scheme，and 2 literature studies indicated that sunitinib was more economical. CONCLUSIONS ：In most cases ，the efficacy and economy of pezoparib in the treatment of mRCC is better than sunitinib and sorafenib ，but real world data shows that sunitinib is more economical.  
        关键词：Sunitinib;Sorafenib;Pazopanib;Pharmacoeconomic evaluation;Literature study;Systematic evaluation   
        346
        |
        10
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609227 false
        发布时间：2022-06-21
      • WANG Li,SUN Wenchong,PEI Ling
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To systematically evaluate the effectiveness and safety of dexmedetomidine versus other controlled hypotension drugs for functional nasal endoscopic surgery ，and to provide evidence-based reference for clinic. METHODS ： Retrieved from PubMed ，EBSCO，Springer，Ovid，Cochrane library ，CJFD，VIP，Wanfang database ，relevant journals and references of the included literature were also searched manually. RCTs about the effectiveness and safety of dexmedetomidine （trial group）versus other controlled hypotension drugs （control group ）for functional nasal endoscopic surgery were collected. After data extraction of included literatures ，quality evaluation with modified Jada quality scoring method ，Meta-analysis was performed by using Rev Man 5.3 software. RERULTS ：A total of 8 RCTs involving 497 patients were included. Meta-analysis results showed that compared with control group ，the ratio patients of hypotensive drug supplement [OR ＝－0.37，95％CI（0.21，0.65），P＝0.000 6] and the bleeding volume [MD ＝－77.74，95％CI（－99.52，－55.96），P＜0.001] of trial groups were lower ；hemodynamics such as MAP during extubation [MD ＝－13.40，95％CI（－16.24，－10.56），P＜0.001] and heart rate during extubation [MD ＝－33.13， 95％CI（－33.40，－26.87），P＜0.001] was more stable during extubation ；quality score of Fromme surgical field was higher [MD ＝ －0.80，95％CI（－0.96，－0.65），P＜0.001]；while the incidence of chill [OR ＝0.37，95％CI（0.18，0.75），P＝0.006]，nausea and vomit [OR ＝0.28，95％CI（0.14，0.59），P＝0.008] were lower. CONCLUSIONS ：Dexmedetomidine has a certain advantage than routine drugs for controlled hypotension during nasal endoscopic surgery ，and with better safety.  
        关键词：Dexmedetomidine;Controlled hypotension;Functional nasal endoscopic surgery;Meta-analysis   
        113
        |
        7
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609218 false
        发布时间：2022-06-21
      • WANG Jing,ZHANG Chenyu,WU Di,HU Xiaowen,GAN Lei,HU Ming,ZHOU Naitong
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide reference for chronic disease man agement service develophed in social pharmacy. METHODS：Questionnaire about the Status Quo of Chronic Disease Management and Service in Social Pharmacy of Chengdu was designed，using the quota sampling method ，social pharmacies in five main urban areas of Chengdu were selected from May to July，2018 to conduct a questionnaire survey （one questionnaire by each social pharmacy ） on the basic situation of social pharmacies，the development of chronic disease management services ，the cognition of chronic disease management services ，and the challenges faced by chronic disease management services ，and suggestions were proposed. RESULTS & CONCLUSIONS ：A total of 272 questionnaires were sent out ，and 252 valid questionnaire were actually collected （effective recovery rate of 92.65％）. Totally 189 sample pharmacies （75.00％） had carried out chronic disease management services ，of which 112 （59.26％） pharmacies had been launched for 1-3 years；87（46.03％）had set up service areas ；68（35.98％）had full-time staff ，and 54 （28.57％）had part-time staff ，most of which were licensed pharmactists. 116（61.37％）had trained related staff for 1-2 times per year. 176（93.12％）pharmacies could provide services such as basic indicator testing （176，93.12％），establishing health records （142，75.13.％），and rational medication guidance for patients （163，86.24％）. According to the survey ，the substantial benefits of chronic disease management services included changing the health status of patients （163，86.24％），improving patients ’trust in the pharmacy and staff （141，74.60％），improving patients ’quality of life （129，68.25％），etc. More than 50％ of pharmacies faced the challenges of limited number of licensed pharmacists （102，53.97％），difficulty in establishing professional teams （112， 59.26％），and lack of trust in services （101，53.44％）. The current chronic disease management service of social pharmacy in Chengdu is in the initial stage of active exploration ，which can bring many benefits to patients and pharmacies ，and is conducive to the promotion of medical and health policies ，but there are some weak links at the same time. It is suggested that relevant government departments should strengthen the support ofpolicies and regulations ， and social pharmacies constantly 85501387。 E-mail：2191043137@qq.com improve professional level and rely on the advantages of “Internet + ”to meet the diverse needs of the public for pharmaceutical care ，and publicity efforts are intensified to · enhance the awareness and participation of patients with chronic diseases.  
        关键词：Chengdu;Social pharmacy;Chronic disease management service;Status quo;Problems;Questionnaire survey   
        272
        |
        14
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609203 false
        发布时间：2022-06-21
      • LI Yan,SHEN Aizong,ZHU Pengli,ZHOU Wan,FANG Ming,NI Weijian,WEI Wei,TANG Liqin
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide method reference for scientifically eva luating the rationality of the use of saxagliptin . METHODS：Based on the drug instructions ，clinical guidelines ，clinical pathways ，related references ，clinical endocrinology department and pharmaceutical experts of a hospital jointly discussed and formulated the evaluation criteria for the rationality of the use of saxagliptin. AHP method was used to assign weights to various indexes of evaluation criteria ；TOPSIS method was used to analyze the use of saxagliptin of 106 cases in the hospital during Nov. 2018-Apr. 2019 retrospectively and evaluate rational drug use. RESULTS ：A total of 6 primary indicators and 12 secondary indicators were established. The first three indicators with a relatively high index weight were indications （with a weight of 0.25），dose and adjustment of administration （with a weight of 0.21）and frequency of administration （with a weight of 0.15）. Among 106 cases，39.6％ of drug use were reasonable ，51.0％ were basically reasonable and 9.4％ were unreasonable. Evaluation results made by weighted TOPSIS were consistent with the actual situation. CONCLUSIONS ：TOPSIS method weighted by AHP is reasonable and feasible for evaluating the rationality of saxagliptin use.  
        关键词：Saxagliptin;AHP;TOPSIS method;Rational evaluation of drug use   
        143
        |
        13
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609189 false
        发布时间：2022-06-21
      • YIN Xueyan,LI Jing,ZHANG Yongjun
        Vol. 31, Issue 5, (2020)
        摘要：OBJECTIVE：To provide reference for the selection of drug treatment plan in patients with Brucellosis combined with liver dysfunction. METHODS ：Clinical pharmacists analyzed drug treatment plan in a patient with Brucellosis combined with liver dysfunction in the First Affiliated Hospital of Medical College of Shihezi University. Referring to Brucella treatment guideline . Consensus statement by the American association of clini - HbA1c cal endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management al - and domestic and foreign clinical information ，the suggesti ons were put forward according to the change of liver dysfunction. RESULTS：The patient had chronic infection and moderate liver injury. The liver dysfunction in this patient was a common complication of Brucellosis. After consultation of doctors and pharmacists ，in consideration of the abnormal liver function ， intravenous drip of levofloxacin （0.5 g，qd）was given in the patient for anti-infection treatment. After the liver function was improved，levofloxacin was stopped ，and intravenous drip of rifampin （0.6 g，qd）and oral administration of doxycycline （100 mg，bid）were given for anti-infection treatment instead ；during the treatment period ，intravenous drip of reduced glutathione （1.8 g，qd）and diammonium glycyrrhizinate （150 mg，qd）were given for anti-inflammatory and liver protecting treatment. During the treatment，the clinical pharmacists closely monitored ADR of patients ，and carried out medication education for patients to improve the compliance. 10 d after medication ，although some of the liver function indexes of the patient did not return to normal ，but Brucellosis and liver dysfunction symptoms were improved. The patient could continue to take the same dose of rifampin and doxycycline after discharge. CONCLUSIONS ：When the patients with Brucellosis have abnormal liver function ，anti-infection treatment should be the main treatment target. The clinical pharmacists should refer to the relevant guidelines and combine with the clinical practice to help doctors adjust the treatment plan ，so as to ensure the safety and effectiveness of the patients ’medication.  
        关键词：Brucellosis;Liver dysfunction;Clinical pharmacist;Rational drug use   
        231
        |
        13
        |
        0
        <HTML>
        <L-PDF><Meta-XML>
        <引用本文> <批量引用> 27609180 false
        发布时间：2022-06-21
      0